674 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year? http://www.zacks.com/stock/news/734952/has-eli-lilly-and-lly-outpaced-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-734952 Jan 27, 2020 - Is (LLY) Outperforming Other Medical Stocks This Year?
J&J's Stelara Gets EU Nod for Plaque Psoriasis in Children http://www.zacks.com/stock/news/731608/jjs-stelara-gets-eu-nod-for-plaque-psoriasis-in-children?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-731608 Jan 24, 2020 - Johnson & Johnson (JNJ) receives the European Commission's (EC) nod to the line extension of Stelara to treat six to 11-year-old pediatric patients with moderate-to-severe plaque psoriasis.
Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP http://www.zacks.com/research-daily/729250/top-stock-analyst-reports-for-pfizer-wells-fargo-sap?cid=CS-ZC-FT-research_daily-729250 Jan 22, 2020 - Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP
Eli Lilly's Shopping Spree Won't Stop With Dermira, CFO Shares Plans For More Deals In 2020 https://www.fool.com/investing/2020/01/17/eli-lillys-shopping-spree-wont-stop-with-dermira-c.aspx?source=iedfolrf0000001 Jan 17, 2020 - The Midwest's largest drugmaker isn't finished making mid-sized deals.
Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates http://www.zacks.com/stock/news/722255/pharma-stock-roundup-lly-dermira-buyout-offer-pipeline-regulatory-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-722255 Jan 17, 2020 - Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.
Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction http://www.zacks.com/stock/news/722212/novo-nordisks-ozempic-gets-fda-nod-for-cv-risk-reduction?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-722212 Jan 17, 2020 - Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.
J&J Seeks Label Expansion for Spravato Nasal Spray in EU http://www.zacks.com/stock/news/720650/jj-seeks-label-expansion-for-spravato-nasal-spray-in-eu?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-720650 Jan 16, 2020 - J&J (JNJ) seeks label expansion for its new nasal spray, Spravato (esketamine), for an expanded patient population in Europe.
Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA http://www.zacks.com/stock/news/720624/bristol-myers-opdivo-yervoy-sbla-for-nsclc-accepted-by-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-720624 Jan 16, 2020 - The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.
Eli Lilly and Company's (LLY) CEO Dave Ricks Presents at 38th Annual JPMorgan Healthcare Conference (Transcript) https://seekingalpha.com/article/4316909-eli-lilly-and-companys-lly-ceo-dave-ricks-presents-38th-annual-jpmorgan-healthcare-conference?source=feed_sector_transcripts Jan 14, 2020 - Eli Lilly and Company (NYSE:LLY) 38th Annual JPMorgan Healthcare Conference Call January 14, 2020 5:30 PM ET Company Participants Dave Ricks – Chairman and Chief Executive Officer Conference Call Part
Glaxo Files Marketing Application for Fostemsavir in Europe http://www.zacks.com/stock/news/715692/glaxo-files-marketing-application-for-fostemsavir-in-europe?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-715692 Jan 13, 2020 - Glaxo (GSK) submits an MAA in Europe for its investigational candidate fostemsavir, which is being developed for treating HIV-1 infection in heavily pre-treated adult HIV patients.

Pages: 123456...68

Page 1>